AR106284A1 - CD20 THERAPIES, CD22 THERAPIES AND COMBINATION THERAPIES WITH A CELL EXPRESSING A CH19ERIC ANTIGEN RECEIVER (CAR) FROM CD19 - Google Patents

CD20 THERAPIES, CD22 THERAPIES AND COMBINATION THERAPIES WITH A CELL EXPRESSING A CH19ERIC ANTIGEN RECEIVER (CAR) FROM CD19

Info

Publication number
AR106284A1
AR106284A1 ARP160100962A ARP160100962A AR106284A1 AR 106284 A1 AR106284 A1 AR 106284A1 AR P160100962 A ARP160100962 A AR P160100962A AR P160100962 A ARP160100962 A AR P160100962A AR 106284 A1 AR106284 A1 AR 106284A1
Authority
AR
Argentina
Prior art keywords
therapies
car
ch19eric
combination
cell expressing
Prior art date
Application number
ARP160100962A
Other languages
Spanish (es)
Inventor
Zhou Li
Zhang Jimin
Tran Thai
Ruella Marco
Orlando Elena
Loew Andreas
Li Na
Lei Ming
Young Kim Ju
H June Carl
Huang Lu
Highfill Steven
Gill Saar
Kumar Dakappagari Naveen
Brogdon Jennifer
Brannetti Barbara
Mary Bordeaux Jennifer
Bitter Hans
Original Assignee
Novartis Ag
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Pennsylvania filed Critical Novartis Ag
Publication of AR106284A1 publication Critical patent/AR106284A1/en

Links

Abstract

Se proporciona composiciones y métodos para tratar enfermedades asociadas con la expresión de CD19, por ejemplo, mediante la administración de una célula T recombinante que comprende el CAR de CD19 tal como se describe en el presente documento, en combinación con uno o más inhibidores de células B, por ejemplo, inhibidores de una o más de CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, o CD79a. También se proporciona dominios de unión a antígeno y moléculas de CAR que se dirigen a CD20 y CD22 y usos, por ejemplo como monoterapia o en terapia de combinación. También se proporciona kits y composiciones descritas en el presente documento.Compositions and methods for treating diseases associated with the expression of CD19 are provided, for example, by the administration of a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more cell inhibitors. B, for example, inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. Also provided are antigen-binding domains and CAR molecules that target CD20 and CD22 and uses, for example as monotherapy or in combination therapy. Kits and compositions described herein are also provided.

ARP160100962A 2015-04-08 2016-04-08 CD20 THERAPIES, CD22 THERAPIES AND COMBINATION THERAPIES WITH A CELL EXPRESSING A CH19ERIC ANTIGEN RECEIVER (CAR) FROM CD19 AR106284A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562144497P 2015-04-08 2015-04-08

Publications (1)

Publication Number Publication Date
AR106284A1 true AR106284A1 (en) 2018-01-03

Family

ID=61158546

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100962A AR106284A1 (en) 2015-04-08 2016-04-08 CD20 THERAPIES, CD22 THERAPIES AND COMBINATION THERAPIES WITH A CELL EXPRESSING A CH19ERIC ANTIGEN RECEIVER (CAR) FROM CD19

Country Status (1)

Country Link
AR (1) AR106284A1 (en)

Similar Documents

Publication Publication Date Title
CO2017010190A2 (en) Cd20 therapies, cd22 therapies and combination therapies with a cell that expresses a chimeric antigen (car) receptor of cd19
MX2018010733A (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore.
MX2022010623A (en) Treatment of cancer using anti-cd19 chimeric antigen receptor.
AR110676A1 (en) TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS
MX2019001469A (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule.
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
CO2017000506A2 (en) Chimeric cll-1 antigen receptor
BR112019001570A2 (en) chimeric antigen receptor combination therapies and pd-1 inhibitors
BR112017013176A2 (en) chimeric antigen receptors and methods for using them
CO2017004516A2 (en) Humanized anti-ox40 antibodies
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2017001008A (en) Treatment of cancer using a cd33 chimeric antigen receptor.
MX2020001450A (en) Methods and compositions for reducing immunosupression by tumor cells.
PE20161392A1 (en) COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCTION, AND ITS USES
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
GT201600171A (en) ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
AR102879A1 (en) METHODS FOR THE TREATMENT OF BRAIN TUMORS
BR112017022838A2 (en) kappa myeloma antigen chimeric antigen receptors and their uses
AR117685A1 (en) CHEMERICAL ANTIGEN AND T-CELL RECEPTORS AND METHODS OF USE
PH12016501366A1 (en) Novel anti-baff antibodies
MX2019000641A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (en) Novel anti-emr2 antibodies and methods of use.
MX2017007097A (en) Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma).